Michael Korn, MD, CMO of Caris Life Sciences discusses the enrichment of alterations in targetable molecular pathways in KRAS wild-type pancreatic cancer.
Read here:Â https://meetinglibrary.asco.org/record/186629/abstract
Michael Korn, MD on Targetable Molecular Pathways in KRAS Wild-Type
